US biotech Sirnaomics has won Food and Drug Administration (FDA) approval to test its STP705 treatment, an RNA inference (RNAi) candidate, for bile duct cancer. At the time, the company said it planned to have two clinical trials running before the end of the year, and it plans to move ahead quickly with STP705 in The U.S., Europe and China, where it has a longstanding partnership with Guangzhou Xiangxue Pharma. It has already been trialled for scar-reduction treatment. Sirnaomics said STP705 downregulated cancer-associated fibroblast activity in and around a tumour which restricted its growth. The company is also working on the development of RNAi treatments that target other types of cancer including lung cancer, prostate cancer and pancreatic cancer. It raised $25m from Chinese investors in June to continue its work. Two clinical trials are planned for later this year in the US, Europe and China where it has a partnership with Guangzhou Xiangxue Pharma.
US biotech Sirnaomics has won Food and Drug Administration (FDA) approval to test its STP705 treatment, an RNA inference (RNAi) candidate, for bile duct cancer. It has already been trialled for scar-reduction treatment. Sirnaomics said STP705 downregulated cancer-associated fibroblast activity in and around a tumour which restricted its growth. The company is also working on the development of RNAi treatments that target other types of cancer including lung cancer, prostate cancer and pancreatic cancer. It raised $25m from Chinese investors in June to continue its work. Two clinical trials are planned for later this year in the US, Europe and China where it has a partnership with Guangzhou Xiangxue Pharma.